Skip to main content
All Posts By

Gayle Mineo

IVIEW Therapeutics Therapeutics Announces Topline Results

By Portfolio News, iView Therapeutics
IVIEW Therapeutics Announces Topline Results from Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe for Dry Eye Disease CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ -- IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced positive topline data from its Phase 1/2 clinical trial evaluating 2 concentrations…
Read More

Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer™

By Portfolio News, KaloCyte
Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer™   Partnership highlights Scorpius’ expertise in supporting innovative therapeutic programs DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced its…
Read More

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial

By Palvella Therapeutics, Portfolio News
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies   Publication reports 10% of participants wereither "Much Improved" or "Very Much Improved" as rated by the Clinician…
Read More

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial

By Palvella Therapeutics, Portfolio News
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations   Phase 2 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of cutaneous venous malformations (cutaneous VMs)…
Read More

Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of VIPER-101

By Portfolio News, Vittoria Biotherapeutics
Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of VIPER-101   Trial is evaluating VIPER-101, a novel, gene edited, autologous dual-population CAR-T therapy in patients with T cell lymphoma VIPER-101 was developed with Vittoria’s proprietary Senza5 platform that features CD5 modulation and a proprietary 5-day  manufacturing…
Read More

Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round

By Portfolio News, Tolerance Bio
Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases   World-class leaders in the thymus, immunology, oncology, cell therapy, and drug development will inform and support the Company’s efforts to preserve, restore, and manipulate the thymus to address…
Read More

Accelerated Biosciences and Stemmatters Collaborate to Offer iPSC Derived from Human Trophoblast Stem Cells

By Portfolio News, Accelerated Biosciences
Accelerated Biosciences and Stemmatters Collaborate to Offer iPSC Derived from Human Trophoblast Stem Cells   PHILADELPHIA--December 16, 2024 (BUSINESS WIRE)--Accelerated Biosciences and Stemmatters are thrilled to announce their strategic partnership aimed at co-developing and co-marketing human induced pluripotent stem cells (“iPSC”) derived from human trophoblast stem cells (“hTSC”). By utilizing…
Read More